Four September publications offer useful lessons in emergency care, neurology and evidence interpretation. Their value is not that each changes practice immediately: each helps separate a reported finding from a justified clinical conclusion.
1. Pyometra: distinguish patient risk from antibiotic assumptions
Evidence: Retrospective multicentre surgical cohort; 625 dogs. Published September 9, 2026. Of 625 dogs undergoing ovariohysterectomy, 604 survived. Sepsis and increased preoperative creatinine were associated with poorer outcomes or longer hospitalization. Among nonseptic dogs, survival did not differ according to receipt of preoperative/intraoperative antimicrobials.
What this means: That association does not demonstrate that antibiotics are unnecessary, establish equivalence, or justify withholding them in sepsis. Treatment selection and other differences may confound retrospective results.
Study takeaway: In a case discussion, distinguish severity assessment, surgical source control and antimicrobial indication rather than assuming one treatment explains the outcome. Jones et al., JAVMA; primary abstract.
2. Severe thoracolumbar IVDE: a promising intervention still needs comparative benefit
Evidence: Randomized pilot involving 32 paraplegic dogs without pain perception; published September 18, 2026. Dogs underwent decompressive surgery and received control treatment, platelet-rich plasma or erythropoietin. Twenty-four of 32 walked by three months, but overall outcomes did not differ between groups.
What this means: The study did not demonstrate a routine benefit from either adjunct. A small pilot also cannot establish that an intervention has no effect. The combined recovery percentage should not be presented as an individual patient's prognosis.
Study takeaway: Ask whether an apparent recovery is better than the comparison group - not merely whether recovery occurred after treatment. Janzen et al., Veterinary Surgery; primary abstract.
3. Eprinomectin neurotoxicosis in cats: normal bloodwork is not exclusion
Evidence: Clinical review; published September 16, 2026. The review describes neurological toxicity following labelled eprinomectin doses in cats deficient in P-glycoprotein. Signs can include dilated pupils, incoordination, weakness and tongue paresis, despite unremarkable routine bloodwork. Recovery may require prolonged supportive care; no established antidote is identified.
What this means: This is not a comparative treatment trial. Intravenous lipid emulsion should not be described as reliably effective, particularly in homozygous MDR1-affected cats.
Study takeaway: As a clinical reasoning inference, exposure history and neurological examination remain important when routine laboratory results appear reassuring. Feeding and supportive-care needs deserve attention rather than assuming a quick reversal. Mealey et al., JVECC; primary abstract.
4. A feline SOFA-derived score: calculable does not mean validated
Evidence: Prospective, single-centre feasibility cohort; 23 cats; published September 21, 2026. A human-derived organ-dysfunction framework could be calculated in the enrolled cats, but its component thresholds raised concerns. The sample was small and predominantly nonseptic; it did not validate a mortality prediction tool.
What this means: Demonstrating that a score can be collected is different from demonstrating reliable prognostic performance. A number should not become an individual mortality estimate without appropriate validation.
Study takeaway: Identify whether a paper evaluates feasibility, discrimination, calibration or a patient-important outcome before putting its score into practice. Codea et al., Life; primary article.
Bottom line
These papers reward four habits: separate association from causation, compare interventions fairly, avoid false reassurance from an incomplete assessment, and demand validation before adopting prognostic scores.
Reading scope and primary sources
Source checks used accessible primary abstracts/publisher summaries; the feline scoring paper additionally had indexed primary full-text excerpts. This is not a comprehensive systematic review. No dosage or treatment protocol is proposed.
Titles below are concise identifying titles, not verbatim full bibliographic titles; exact IDs resolve to publisher metadata. No claim of full-text review for all studies.
- Pyometra: sepsis, creatinine and antibiotic outcomes
Study publication: 2026-09-09. Retrospective 625-dog surgical cohort. DOI: 10.2460/javma.26.05.0367. - Erythropoietin/PRP adjuncts after severe thoracolumbar IVDE
Study publication: 2026-09-18. Randomized 32-dog pilot. DOI: 10.1111/vsu.70158. - Eprinomectin neurotoxicosis management in cats
Study publication: 2026-09-16. Clinical review. DOI: 10.1111/vec.70164. - Feline SOFA-derived organ-dysfunction score feasibility
Study publication: 2026-09-21. Prospective 23-cat feasibility cohort. DOI: 10.3390/life16091575.
DVMReady provides independent educational support. Verify current examination, licensing, and clinical information with the relevant official source and professional references.
Official Sources
Check current guidance against the original sources.
- Pyometra: sepsis, creatinine and antibiotic outcomes (primary abstract)
- Erythropoietin/PRP adjuncts after severe thoracolumbar IVDE (primary abstract)
- Eprinomectin neurotoxicosis management in cats (primary abstract)
- Feline SOFA-derived organ-dysfunction score feasibility (indexed primary text/abstract)